Загрузка...
Enzalutamide induced acute generalized exanthematous pustulosis
INTRODUCTION: Enzalutamide (Xtandi®) is a new potent inhibitor of the signaling pathway for the androgen receptor with a half-life of 5.8 days. It has been on the market for the treatment of metastatic castration-resistant prostate cancer since November 2013. OBJECTIVE: We report the first case of a...
Сохранить в:
| Опубликовано в: : | J Dermatol Case Rep |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Specjalisci Dermatolodzy
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5124370/ https://ncbi.nlm.nih.gov/pubmed/27900064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3315/jdcr.2016.1226 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|